Spryte Medical Announces First Human Use of Novel Intravascular Brain Imaging Technology, Published in Science Translational Medicine
May 15 2024 - 2:29PM
Business Wire
The first intravascular imaging technology specifically designed
for the brain could have implications in stroke and other
neurovascular diseases
Spryte Medical, an intravascular imaging and AI company today
announced the publication of their first-in-human study of its
neuro Optical Coherence Tomography (nOCT) technology in the peer
reviewed journal Science Translational Medicine, entitled
“Volumetric microscopy of cerebral arteries with a miniaturized
optical coherence tomography imaging probe.” This research, hailed
as a significant milestone by researchers, is the first to
demonstrate the ability to bring intravascular imaging to the
brain, helping clinicians to better see the pathology associated to
neurovascular disease, with potential future implications for the
treatment of stroke and related conditions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240515757948/en/
Reprinted with permission from AAAS.
“This is an incredibly exciting milestone for the field of
neuro-intervention. Direct imaging of the pathology and its
relationship to devices will transform treatment decisions, and the
fundamental understanding of cerebrovascular pathology,” said
Matthew Gounis, Professor and Vice Chair of Research in the
Department of Radiology at UMass Chan Medical School, Worcester,
MA. “Revolutions in imaging technology, from the discovery of
x-rays over 120 years ago to 3-dimensional imaging in the
angiography suite more than 20 years ago, occur roughly once in a
generation.”
The procedures, performed by Vitor Mendes Pereira, MD, of St
Michael’s Hospital and University of Toronto, Canada, and Pedro
Lylyk, MD, of Clínica la Sagrada Familia, Buenos Aires demonstrated
successful navigation and imaging with the nOCT probe in 32
patients undergoing routine investigation or treatment for
cerebrovascular disease. The device is not approved for human use
in the USA or commercially available. All patients were treated
with appropriate ethical approval.
“The Spryte nOCT technology is an imaging probe, sized like a
guidewire, that navigates seamlessly through the brain vessels
using our usual neuro-interventional techniques. The system and
imaging probes performed well, integrating with our workflow, and
provided us with incredible images and critical information that we
cannot obtain with any other technology,” said Pereira.
The paper underscores the significant scientific achievement
made by Spryte in miniaturizing OCT technology to safely navigate
the blood vessels of the brain while providing a high-resolution,
micron-level image. The goal is to allow physicians to better
understand anatomy, pathology and device implants, better informing
therapeutic decision making. The implications of this technology in
improving the treatment of patients suffering neurovascular disease
are only starting to surface. Science Translational Medicine is a
perfect journal to showcase this work, bringing together scientific
innovation and medical application.
“This study provides proof of concept for using optical
coherence tomography devices to better understand cerebrovascular
pathology and intervention for a range of conditions in the human
brain,” said editor Brandon Berry from Science Translational
Medicine.
About Spryte Medical: Spryte Medical is an intravascular
imaging, AI, and data company headquartered in Bedford,
Massachusetts. The unique imaging and data platform is
purpose-built to accelerate understanding of target diseases,
facilitate the development of novel therapies and ensure optimal
treatment delivery for the benefit of patients worldwide. Spryte
has selected neurovascular disease as the company’s initial area of
focus. While intravascular imaging has contributed to significant
improvements in cardiovascular care, the fundamental limitations of
current technologies have precluded their use in the small,
tortuous, intracranial vasculature. Spryte’s technology, however,
overcomes these limitations and integrates with established
procedural workflow, providing it the opportunity to become the
first and only intracranial imaging technology available to
clinicians worldwide that enables both intraluminal imaging as well
as volumetric microscopy of the neurovascular vessels.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515757948/en/
Media Contact Kristin Rose Jutras 908.947.0500 x719
Kristin.jutras@tmstrat.com